{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T23:14:32Z","timestamp":1783379672285,"version":"3.54.6"},"reference-count":33,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.urolonc.2026.04.297","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T21:24:23Z","timestamp":1779485063000},"page":"4-12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Adverse pathology and low tumor volume in biopsy Gleason 3 + 4 prostate cancer: Toward safe expansion of active surveillance and focal therapy"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1633-784X","authenticated-orcid":false,"given":"Yu","family":"Ozawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcio Covas","family":"Moschovas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Sandri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohan","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shady","family":"Saikali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari","family":"Diamond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vipul","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2026.04.297_bib0001","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1186\/s12894-023-01314-6","article-title":"Active surveillance should be considered for select men with grade Group 2 prostate cancer","volume":"23","author":"Pekala","year":"2023","journal-title":"BMC Urol"},{"key":"10.1016\/j.urolonc.2026.04.297_bib0002","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s12894-023-01315-5","article-title":"Active surveillance should not be routinely considered in ISUP grade group 2 prostate cancer","volume":"23","author":"Gandaglia","year":"2023","journal-title":"BMC Urol"},{"key":"10.1016\/j.urolonc.2026.04.297_bib0003","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1038\/s41391-021-00369-6","article-title":"Conventional radical versus focal treatment for localised prostate cancer: a propensity score weighted comparison of 6-year tumour control","volume":"24","author":"van Son","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.urolonc.2026.04.297_bib0004","unstructured":"EAU Guidelines. Edn. presented at the EAU Annual Congress Madrid, Spain 2025."},{"key":"10.1016\/j.urolonc.2026.04.297_bib0005","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/s41391-023-00702-1","article-title":"The state of focal therapy in the treatment of prostate cancer: the university of California collaborative (UC-Squared) consensus statement","volume":"27","author":"Javier-DesLoges","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.urolonc.2026.04.297_bib0006","unstructured":"NCCN guideline: national Comprehensive Cancer Network. NCCN Guidelines version 5. 2026: prostate cancer. NCCN Clinical Practice Guidelines in oncology (NCCN Guidelines). [Accessed 22 March 2026]. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf."},{"key":"10.1016\/j.urolonc.2026.04.297_bib0007","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/j.juro.2016.06.102","article-title":"Active surveillance for intermediate risk prostate cancer: survival outcomes in the Sunnybrook experience","volume":"196","author":"Musunuru","year":"2016","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.04.297_bib0008","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.euf.2016.10.010","article-title":"Variability in outcomes for patients with intermediate-risk prostate cancer (Gleason score 7, international society of urological pathology Gleason group 2-3) and implications for risk stratification: a systematic review","volume":"3","author":"Kane","year":"2017","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.urolonc.2026.04.297_bib0009","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.euo.2019.08.001","article-title":"Concordance between biopsy and radical prostatectomy pathology in the era of targeted biopsy: a systematic review and meta-analysis","volume":"3","author":"Goel","year":"2020","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.urolonc.2026.04.297_bib0010","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/JU.0000000000001519","article-title":"Selecting patients with favorable risk, grade group 2 prostate cancer for active surveillance\u2014Does magnetic resonance imaging have a role?","volume":"205","author":"Stonier","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.04.297_bib0011","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.juro.2018.08.043","article-title":"PI-RADS version 2 category on 3 tesla multiparametric prostate magnetic resonance imaging predicts oncologic outcomes in Gleason 3 + 4 prostate cancer on biopsy","volume":"201","author":"Faiena","year":"2019","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.04.297_bib0012","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.euf.2022.09.011","article-title":"Expanding active surveillance criteria for low- and intermediate-risk prostate cancer: can we accurately predict the risk of misclassification for patients diagnosed by multiparametric magnetic resonance imaging-targeted biopsy?","volume":"9","author":"Diamand","year":"2023","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.urolonc.2026.04.297_bib0013","doi-asserted-by":"crossref","first-page":"415.e1","DOI":"10.1016\/j.urolonc.2016.03.019","article-title":"Standardizing the definition of adverse pathology for lower risk men undergoing radical prostatectomy","volume":"34","author":"Kozminski","year":"2016","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2026.04.297_bib0014","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.35684","article-title":"Alternate definitions of adverse pathology to predict a very high risk of metastasis in men with intermediate- and low-risk prostate cancer","volume":"131","author":"Castaneda","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2026.04.297_bib0015","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.eururo.2020.05.041","article-title":"Modified apical dissection and lateral prostatic fascia preservation improves early postoperative functional recovery in robotic-assisted laparoscopic radical prostatectomy: results from a propensity score-matched analysis","volume":"78","author":"Covas Moschovas","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.04.297_bib0016","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.eururo.2018.12.014","article-title":"lines for reporting of statistics for clinical research in urology","volume":"75","author":"Assel","year":"2019","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2026.04.297_bib0017","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.euo.2025.01.009","article-title":"Active Surveillance of Grade Group 2 Prostate Cancer: Oncological Outcomes from a Contemporary European Cohort","volume":"8","author":"Baboudjian","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.urolonc.2026.04.297_bib0018","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.euo.2022.03.007","article-title":"A multivariable approach using magnetic resonance imaging to avoid a protocol-based prostate biopsy in men on active surveillance for prostate cancer-data from the international multicenter prospective PRIAS study","volume":"5","author":"Luiting","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.urolonc.2026.04.297_bib0019","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1007\/s00345-022-04161-6","article-title":"Percentage gleason pattern 4 and PI-RADS score predict upgrading in biopsy grade group 2 prostate cancer patients without cribriform pattern","volume":"40","author":"van der Slot","year":"2022","journal-title":"World J Urol"},{"key":"10.1016\/j.urolonc.2026.04.297_bib0020","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.euf.2017.05.011","article-title":"Risk of upgrading and upstaging among 10 000 patients with gleason 3+4 favorable intermediate-risk prostate cancer","volume":"5","author":"Yang","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.urolonc.2026.04.297_bib0021","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.euo.2020.08.001","article-title":"Expanding active surveillance inclusion criteria: a novel nomogram including preoperative clinical parameters and magnetic resonance imaging findings","volume":"5","author":"Lantz","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.urolonc.2026.04.297_bib0022","doi-asserted-by":"crossref","first-page":"71.e1","DOI":"10.1016\/j.urolonc.2014.07.007","article-title":"Can we expand active surveillance criteria to include biopsy gleason 3+4 prostate cancer? A multi-institutional study of 2,323 patients","volume":"33","author":"Ploussard","year":"2015","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2026.04.297_bib0023","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.eururo.2016.08.043","article-title":"Adverse disease features in Gleason score 3 + 4 \u201cfavorable intermediate-risk\u201d prostate cancer: implications for active surveillance","volume":"72","author":"Morlacco","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.04.297_bib0024","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eururo.2020.08.019","volume":"79","author":"Radtke","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.04.297_bib0025","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.1439","article-title":"Time trends and variation in the use of active surveillance for management of low-risk prostate cancer in the US","volume":"6","author":"Cooperberg","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.urolonc.2026.04.297_bib0026","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1097\/JU.0000000000000621","article-title":"African American race is not associated with risk of reclassification during active surveillance: results from the Canary prostate cancer active surveillance study","volume":"203","author":"Schenk","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.04.297_bib0027","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1001\/jamaoncol.2019.0826","article-title":"Association of black race with prostate cancer-specific and other-cause mortality","volume":"5","author":"Dess","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.urolonc.2026.04.297_bib0028","doi-asserted-by":"crossref","first-page":"e1073","DOI":"10.1016\/j.clgc.2018.07.001","article-title":"any racial disparity exist in oncologic outcomes after primary cryotherapy for prostate cancer? A matched-pair comparative analysis of the Cryo on-line Data Registry","volume":"16","author":"Aminsharifi","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2026.04.297_bib0029","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.eururo.2012.12.057","article-title":"Prostate cancer risk inflation as a consequence of image-targeted biopsy of the prostate: a computer simulation study","volume":"65","author":"Robertson","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.04.297_bib0030","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/JU.0000000000002685","article-title":"Oncologic outcomes of total length gleason pattern 4 on biopsy in men with grade group 2 prostate cancer","volume":"208","author":"Perera","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.04.297_bib0031","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41391-018-0101-6","article-title":"Validation of the decipher test for predicting adverse pathology in candidates for prostate cancer active surveillance","volume":"22","author":"Kim","year":"2019","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"6","key":"10.1016\/j.urolonc.2026.04.297_bib0032","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1002\/pros.70129","article-title":"Incremental Predictive Value of the Oncotype Genomic Prostate Score for Adverse Pathology in Active Surveillance Candidates","volume":"86","author":"Ozawa","year":"2026","journal-title":"Prostate"},{"key":"10.1016\/j.urolonc.2026.04.297_bib0033","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1002\/bco2.456","article-title":"Focal therapy of prostate cancer: use of artificial intelligence to define tumour volume and predict treatment outcomes","volume":"6","author":"Brisbane","year":"2025","journal-title":"BJUI Compass"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926005065?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926005065?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T22:29:04Z","timestamp":1783376944000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926005065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1078143926005065"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.04.297","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse pathology and low tumor volume in biopsy Gleason 3 + 4 prostate cancer: Toward safe expansion of active surveillance and focal therapy","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.04.297","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}